Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous procedure, conolidine modulates alternate molecular targets. A Science Developments review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://buckminsterv208wzf7.wikiconverse.com/user